ad
This Article
Right arrow Images Only
Right arrow Full Version
Right arrow An erratum has been published
Services
Right arrow E-mail this link to a friend
Right arrow Related text in Red Book
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Articles in Pediatrics
Right arrow reprints & permissions
Right arrow Section 1
Section 2
Section 3
Section 4
Section 5
Appendices

The following text is from an archived Red Book® edition and may not reflect current recommendations or information. To view the current edition, click here.

The first 300 words of the full text of this section appear below.

Section 3. Summaries of Infectious Diseases

Rubella

Clinical Manifestations
Etiology
Epidemiology
Diagnostic Tests
Treatment
Isolation of the Hospitalized Patient
Control Measures

Top
 Next
CLINICAL MANIFESTATIONS:

POSTNATAL RUBELLA. Many cases of postnatal rubella are subclinical. Clinical disease usually is mild and characterized by a generalized erythematous maculopapular rash, lymphadenopathy, and slight fever. The rash starts on the face, becomes generalized in 24 hours, and lasts a median of 3 days. Lymphadenopathy, which may precede rash, often involves posterior auricular or suboccipital lymph nodes, can be generalized, and lasts between 5 and 8 days. Conjunctivitis and palatal enanthem have been noted. Transient polyarthralgia and polyarthritis rarely occur in children but are common in adolescents and adults, especially females. Encephalitis (1:5000 cases) and thrombocytopenia (1:3000 cases) are rare complications. Maternal rubella during pregnancy can result in miscarriage, fetal death, or a constellation of congenital anomalies (congenital rubella syndrome).

CONGENITAL RUBELLA SYNDROME (CRS). The most commonly described anomalies associated with congenital rubella syndrome are ophthalmologic (cataracts, pigmentary retinopathy, microphthalmos, and congenital glaucoma), cardiac (patent ductus arteriosus, peripheral pulmonary artery stenosis), auditory (sensorineural hearing impairment), and neurologic (behavioral disorders, meningoencephalitis, and mental retardation). Neonatal manifestations of congenital rubella syndrome include growth retardation, interstitial pneumonitis, radiolucent bone disease, hepatosplenomegaly, thrombocytopenia, and dermal erythropoiesis (so called "blueberry muffin" lesions). Mild forms of the disease can be associated with few or no obvious clinical manifestations at birth. The occurrence of congenital defects is up to 85% if infection associated with maternal rash occurs during the first 12 weeks of gestation, 54% during the first 13 to 16 weeks of gestation, and 25% during the end of the second trimester.


Top
 Previous
Next
ETIOLOGY: Rubella virus is an enveloped, positive-stranded RNA virus classified as a Rubivirus in the Togaviridae family.


Top
 Previous
Next
EPIDEMIOLOGY: Humans are the only source of infection. . . . [Go to Full Text]


Related text in Red Book:

Vaccine Dose

Red Book 2006: 36. [Extract] [Full Version]  

Vaccine Safety and Contraindications

Red Book 2006: 39-41. [Extract] [Full Version]  

Simultaneous Administration of Multiple Vaccines

Red Book 2006: 34. [Extract] [Full Version]  

Immune Globulin (Intramuscular)

Red Book 2006: 55-57. [Extract] [Full Version]  

Immunocompromised Children

Red Book 2006: 71-85. [Extract] [Full Version]  

Human Milk

Red Book 2006: 123-124. [Extract] [Full Version]  

Diseases Preventable by Routine Childhood Immunization

Red Book 2006: 146. [Extract] [Full Version]  

Varicella-Zoster Infections

Red Book 2006: 711-725. [Extract] [Full Version]  

Human Immunodeficiency Virus Infection

Red Book 2006: 378-401. [Extract] [Full Version]  

Measles

Red Book 2006: 441-452. [Extract] [Full Version]  

Mumps

Red Book 2006: 464-468. [Extract] [Full Version]  



This topic has been referenced by these articles:

  • Abbott;, M., Gerber, M. A., Halsey, N. A., Abramson, J. S. (2001). Varicella Vaccine Question. Pediatrics 107: 612-612 [Full Version]  
  • Klein, J. O., Myers, M. G. (2006). Vaccine shortages: why they occur and what needs to be done to strengthen vaccine supply.. Pediatrics 117: 2269-2275 [Full Version]  
  • Muhle, R., Trentacoste, S. V., Rapin, I. (2004). The Genetics of Autism. Pediatrics 113: e472-e486 [Abstract] [Full Version]  
  • Perez, E. E., Bokszczanin, A., McDonald-McGinn, D., Zackai, E. H., Sullivan, K. E. (2003). Safety of Live Viral Vaccines in Patients With Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome). Pediatrics 112: e325-325 [Abstract] [Full Version]  
  • Bonilla, F. A. (2004). SAFETY OF LIVE VIRAL VACCINES IN PATIENTS WITH CHROMOSOME 22Q11.2 DELETION SYNDROME (DiGEORGE SYNDROME/VELOCARDIOFACIAL SYNDROME). Pediatrics 114: 550-550 [Full Version]  
  • (2006). Reisinger KS, Hoffman Brown ML, Xu J, et al. A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax. PEDIATRICS 2006;117:265-272.. Pediatrics 117: 2338-2338 [Full Version]  
  • Pool, V., Braun, M. M., Kelso, J. M., Mootrey, G., Chen, R. T., Yunginger, J. W., Jacobson, R. M., Gargiullo, P. M. (2002). Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After Measles-Mumps-Rubella Vaccine in the United States. Pediatrics 110: e71-71 [Abstract] [Full Version]  
  • Bekker, V., Scherpbier, H., Pajkrt, D., Jurriaans, S., Zaaijer, H., Kuijpers, T. W. (2006). Persistent Humoral Immune Defect in Highly Active Antiretroviral Therapy-Treated Children With HIV-1 Infection: Loss of Specific Antibodies Against Attenuated Vaccine Strains and Natural Viral Infection. Pediatrics 118: e315-e322 [Abstract] [Full Version]  
  • Maloney, J., Sicherer, S. H. (2005). No Epidemiological Evidence for Infant Vaccination to Cause Allergic Disease. Pediatrics 116: 542-542 [Full Version]  
  • Halsey, N. A., Hyman, S. L., the Conference Writing Panel, (2001). Measles-Mumps-Rubella Vaccine and Autistic Spectrum Disorder: Report From the New Challenges in Childhood Immunizations Conference Convened in Oak Brook, Illinois, June 12-13, 2000. Pediatrics 107: 84e-84 [Abstract] [Full Version]  
  • Leitch, R., Halsey, N., Hyman, S. L. (2002). MMR--Separate Administration--Has It Been Done?. Pediatrics 109: 172-172 [Full Version]  
  • Piedra, P. A., Gaglani, M. J., Riggs, M., Herschler, G., Fewlass, C., Watts, M., Kozinetz, C., Hessel, C., Glezen, W. P. (2005). Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label Trial. Pediatrics 116: e397-e407 [Abstract] [Full Version]  
  • Zimmerman, L., Reef, S. E. (2001). Incidence of Congenital Rubella Syndrome at a Hospital Serving a Predominantly Hispanic Population, El Paso, Texas. Pediatrics 107: 40e-40 [Abstract] [Full Version]  
  • Miller, L. C., Comfort, K., Kelly, N. (2001). Immunization Status of Internationally Adopted Children. Pediatrics 108: 1050-1051 [Full Version]  
  • Rosenthal, J., Rodewald, L., McCauley, M., Berman, S., Irigoyen, M., Sawyer, M., Yusuf, H., Davis, R., Kalton, G. (2004). Immunization Coverage Levels Among 19- to 35-Month-Old Children in 4 Diverse, Medically Underserved Areas of the United States. Pediatrics 113: e296-e302 [Abstract] [Full Version]  
  • Meissner, H. C., Reef, S. E., Cochi, S. (2006). Elimination of Rubella From the United States: A Milestone on the Road to Global Elimination. Pediatrics 117: 933-935 [Full Version]  
  • Virtanen, M., Peltola, H., Paunio, M., Heinonen, O. P. (2000). Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination. Pediatrics 106: 62e-62 [Abstract] [Full Version]  
  • Nilsson, A., De Milito, A., Engstrom, P., Nordin, M., Narita, M., Grillner, L., Chiodi, F., Bjork, O. (2002). Current Chemotherapy Protocols for Childhood Acute Lymphoblastic Leukemia Induce Loss of Humoral Immunity to Viral Vaccination Antigens. Pediatrics 109: e91-91 [Abstract] [Full Version]  
  • Zerr, D. M., Heath, J., Riggert, D., Marcuse, E. K., Zimmerman, L., Reef, S. E. (2001). Congenital Rubella Infection Control Problem. Pediatrics 108: 1389-1390 [Full Version]  
  • Bascom, S., Miller, S., Greenblatt, J. (2005). Assessment of Perinatal Hepatitis B and Rubella Prevention in New Hampshire Delivery Hospitals. Pediatrics 115: e594-e599 [Abstract] [Full Version]  
  • Patja, A., Mäkinen-Kiljunen, S., Davidkin, I., Paunio, M., Peltola, H. (2001). Allergic Reactions to Measles-Mumps-Rubella Vaccination. Pediatrics 107: 27e-27 [Abstract] [Full Version]  
  • Reisinger, K. S., Hoffman Brown, M. L., Xu, J., Sullivan, B. J., Marshall, G. S., Nauert, B., Matson, D. O., Silas, P. E., Protocol 014 Study Group for ProQuad, , Schodel, F., Gress, J. O., Kuter, B. J. (2006). A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax. Pediatrics 117: 265-272 [Abstract] [Full Version]